Author Archives: Lu Rahman

#Multi-omics #Oncology #Precision medicine #Single-cell analysis

Single-cell Sequencing 101: DNA & multi-omics for precision medicine

Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, Mission Bio reviews how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, therapeutic resistance, disease… Read More

#News

#Bioactive proteins #Cell culture #Cytokines #Whitepaper

Discover future ready bioactive proteins: whitepaper

From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies, says Abcam. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced… Read More

#News

#Sitting Down With

Enhancing the role of multiplexing in high-throughput screening

The latest sponsored DDW Sitting Down With podcast features Paul Wylie, Director of Multiplex at Abcam looking at enhancing the role of multiplexing in high-throughput screening. Among the topics Lu Rahman will be discussing with Wylie will be the key challenges scientists face with biomarker and drug discovery and… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Drug discovery #Informatics #Lab automation #LIMS

Enhancing drug discovery with laboratory informatics and automation

Listen to this article on the DDW Podcast: Laura Marozsan, Scientific Marketing Specialist, Thermo Fisher Scientific, outlines the benefits  of automation in drug discovery. Automation plays a crucial role in modern drug discovery, enabling improvements in efficiency, standardisation, reproducibility and data integrity. An effective automated laboratory contains two main components, physical… Read More

#Exclusive Content #News

#Biomedical research #Drug discovery #Life sciences

£1 million grant will help develop new medicines in Scotland

The University of Dundee has received £1 million from the Wolfson Foundation to contribute to the costs of fitting-out the Tay Cities Regional Innovation Hub with laboratories and facilities required by high-growth biomedical companies seeking to develop new medicines and medical technologies. The Innovation Hub is central to Growing the… Read More

#News

#Biopharma #Drug discovery #Life sciences #R&D

Abcam opens new US site

Abcam has opened a new site in Waltham, MA. The facility is a central part of Abcam’s growth in the US and will serve as a hub for its R&D and commercial activities in the region. “Abcam’s first step toward global expansion was in 2003 at Kendall Square.  Since then,… Read More

#News

#Biologics / Biotechnology #CAR-T #Cell therapy #Immunotherapy #Stem cells

Biotech’s pursuit of next-generation CAR-T

Listen to this article on the DDW Podcast: Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Anti-virals #Covid-19 #Drug development

Large-scale drug analysis reveals potential new Covid-19 antivirals

Researchers at the Francis Crick Institute and University of Dundee have screened thousands of drug and chemical molecules and identified a range of potential antivirals that could be developed into new treatments for Covid-19 or in preparation for future coronavirus outbreaks. While Covid-19 vaccines are being rolled out, there are… Read More

#Editor's Choice #News #Trending News

#Aptamers #CAR-T #Immunotherapy #Oncology

Research collaboration will develop bispecific agents for oncology

Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with… Read More

#Cancer Research #News

#Drug discovery #Genetics / genomics #Genomics

Reproducibility in single cell genomic analysis

Listen to this article on the DDW Podcast: By Andrew Gane, Diagnostics Strategy & Technology Manager, Cytiva A cell is a base unit in biology where the genome is transcribed and translated into function. Our traditional understanding of cells rests heavily on studying cells in tissues as an identical population, with… Read More

#Exclusive Content #News

#CRISPR #CRISPR screening #Drug targets #Drug validation #Macrophages

Understanding macrophages for future therapy success: event

Macrophages are involved in many different disease states, so understanding more about how these cells are regulated is important for future therapies for a range of diseases.  CD14, a co-receptor for bacterial lipopolysaccharide, and can potentiate inflammatory signalling when upregulated on myeloid cells during differentiation. Join DDW for this webinar,… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Deep learning #Drug discovery #Pharmaceutical

Opportunities and challenges for AI in drug discovery

By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past decade, a new industry has arisen that seeks to apply artificial intelligence (AI), or more aptly machine learning (ML) technologies,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

Webinar: Improving work rate, productivity and getting to market faster

We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a… Read More

#News

#Drug efficacy #Drug safety #Drug toxicity #Preclinical investigations

How to enhance the predictability of preclinical development: webinar

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human… Read More

#Editor's Choice #News